Chimerix Inc (CMRX) Shares Sold by Citadel Advisors LLC
Citadel Advisors LLC reduced its stake in shares of Chimerix Inc (NASDAQ:CMRX) by 65.5% during the 2nd quarter, Holdings Channel reports. The firm owned 35,611 shares of the biopharmaceutical company’s stock after selling 67,575 shares during the quarter. Citadel Advisors LLC’s holdings in Chimerix were worth $169,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of CMRX. Wells Fargo & Company MN raised its position in Chimerix by 46.1% in the 1st quarter. Wells Fargo & Company MN now owns 33,569 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 10,598 shares during the last quarter. Victory Capital Management Inc. raised its position in Chimerix by 10.9% in the 1st quarter. Victory Capital Management Inc. now owns 284,374 shares of the biopharmaceutical company’s stock valued at $1,479,000 after buying an additional 27,950 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Chimerix by 12.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,317,142 shares of the biopharmaceutical company’s stock valued at $12,049,000 after buying an additional 259,424 shares during the last quarter. MetLife Investment Advisors LLC purchased a new stake in Chimerix in the 1st quarter valued at $127,000. Finally, A.R.T. Advisors LLC purchased a new stake in Chimerix in the 1st quarter valued at $252,000. Institutional investors and hedge funds own 72.98% of the company’s stock.
A number of equities research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Chimerix in a research report on Friday, September 7th. Zacks Investment Research lowered Chimerix from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th. Finally, ValuEngine raised Chimerix from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. Chimerix currently has an average rating of “Hold” and an average target price of $7.08.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05. The business had revenue of $1.19 million during the quarter, compared to analyst estimates of $0.94 million. Chimerix had a negative return on equity of 34.94% and a negative net margin of 1,582.64%. equities analysts anticipate that Chimerix Inc will post -1.66 earnings per share for the current fiscal year.
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Read More: Penny Stocks
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix Inc (NASDAQ:CMRX).
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.